RealTest In Action.
Actionable Results.

Fair concern - it's exactly why we publish the .rts source and the methodology, not just a results image. Every strategy in the paid catalog ran the same gauntlet: in-sample backtest, out-of-sample check on data the script never saw during development, a 2008 crisis-window stress test (we cull anything where most of the drawdown is concentrated in one regime), and stage-floor culls on Sharpe and MAR. The kills are documented too - the Graveyard page lists what got rejected and why. Because the .rts is plain text and you run it yourself in RealTest, you don't have to take our word for the numbers - you can rerun the backtest on your own Norgate subscription and confirm.

For the strategies we trade with our own capital - the Hall of Fame - yes, and that live history is part of why they cleared every gate. But those aren't for sale. The catalog is for strategies that cleared our return bar but missed at least one Hall of Fame criterion. They have published backtests through 2024 plus the .rts file, so you can paper-trade them forward on Interactive Brokers (or any broker that consumes a CSV order list) before risking real capital. That's a fair compromise: the research is real, and you get to verify it on live data on your own broker before sizing up.

Two reasons, both honest. First, we are trading our best strategies - those sit in the Hall of Fame and run our own book. What's for sale are concepts that cleared the return bar but didn't earn a Hall of Fame slot (drawdown clustered in one regime, Sharpe a notch below our promotion floor, behavior that doesn't fit the portfolio we already run). Second, even profitable strategies hit a capital ceiling - 15% CAGR on a six-figure account doesn't change much, and adding more strategies to one book eventually creates fill collisions and correlation drag. Selling research we've already paid for in time and compute is more efficient than letting it sit unused. The arithmetic only works because every buyer runs their own capital on their own broker on their own clock - no shared book.

Not for the catalog strategies, no. The Hall of Fame - what we actually trade - isn't for sale at any price. The for-sale set are strategies whose edge was real enough to clear our return floor but had a structural feature (regime concentration, modest Sharpe, etc.) that disqualified them from our live portfolio. US equities is also deep enough that retail-sized copies of a mean-reversion or trend strategy don't move price, so independent execution on independent capital doesn't dilute anyone's fills. If we thought selling a particular strategy would crowd it out of profitability, it would not be in the catalog.

Code. A plain-text .rts file you load into RealTest yourself. No signal feed, no managed account, no opaque black box, no subscription. One-time purchase, you own the file, you run it on your own machine, you decide which broker to wire it into. If you've never run a RealTest strategy before, the automation page on this site walks through the RealTest -> OrderClerk -> Interactive Brokers handoff that gets daily orders to market.

We agree with the premise - most retail algo marketplaces optimize for screenshots, not for honest research. We try to do the inverse: every strategy is a real artifact from our research pipeline, not something written for the catalog. Every page links the underlying .rts so the code is inspectable. Kills are published alongside winners. The Hall of Fame - the set we trade with our own money - is publicly named and not for sale. None of that proves anything by itself, but it lowers the cost of due diligence: read the .rts, rerun the backtest on your own data, walk through the trade list, and decide.

We sell research and source code, not investment advice or managed accounts. We are not your broker, your investment adviser, or your portfolio manager. You execute on your own broker with your own capital and you alone decide what to trade and when. That's the same posture as a quant textbook or a published academic strategy. Full risk disclosure is linked in the footer, and we'd encourage anyone planning to deploy live capital to read it. If you want managed money or copy-trading, this is the wrong storefront - you'd want Darwinex, Collective2, or similar.

Honest answer: support is limited by design. A purchase includes the .rts source, the methodology documentation, and the pipeline notes for that concept. If RealTest itself ships an update that breaks parsing on a file we sold, we'll fix it and re-issue. We will not promise to keep tuning a strategy indefinitely - markets evolve, edges decay, and that's true for every quantitative strategy regardless of seller. What we are committing to is that what you bought is what we said it was: a real pipeline artifact with documented metrics and reproducible code. Free-tier strategies are as-is, no support.

Lease, profit-split, and copy-trading all create an ongoing relationship that puts us closer to managing other people's money - a regulatory category we deliberately don't want to operate in. A one-time code sale keeps the line clean: you bought a piece of research, you own it, you're responsible for what you do with it. It also keeps incentives aligned - we don't get paid more when you take more risk, and we have no reason to push you to size up. If profit-split or copy-trade is your preferred model, the venues that handle the compliance overhead (Darwinex, Collective2, Stryker for futures) exist for exactly that.

Minimum: a RealTest license (mhptrading.com) to run the .rts and a Norgate Platinum subscription to reproduce the published backtest on point-in-time data. For live trading: Interactive Brokers plus OrderClerk (bundled with RealTest at no extra cost) to push daily orders from the .rts output to the broker. The automation page on this site has the full walkthrough, daily timeline, and the first-time-setup gotchas. Free-tier strategies have the same data requirement; Norgate's free trial only covers a recent window, so reproducing the full backtest history needs the paid tier.